Lixisenatide · source year
5 selected, source-linked Lixisenatide records carrying a 2016 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
5 selected records.
3 represented types.
5 distinct public records.
Cited chronology
Regulatory
DailyMed lists Structured Product Labeling version 1 for the reviewed Lixisenatide label family with a published date of 2016-11-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory
The official Drugs@FDA dataset lists original submission 1 for BLA 208471 with status AP dated 2016-07-27, and names lixisenatide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 27200667 at 2026-07-30T21:38:23.145Z. PubMed recorded a metadata revision date of 2016-05-21 and an Entrez history date of 2016-05-21. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02276196 at 2026-07-30T21:37:20.821Z. Its registry update date was 2016-04-29, and PeptideScanner's reviewed identity mapping was lixisenatide.
Source: ClinicalTrials.gov ↗
Regulatory
The Federal Register published notice 2016-05931, attributed to FDA and its parent HHS department, on 2016-03-16. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Lixisenatide.
Source: Federal Register via GovInfo ↗